BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2807622
Number of visits today
42
Number of downloads
2059309
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Zhang P, Xu K, Wang J, Zhang J, Quan H. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma. BMC Cancer 2021;21:1285. [PMID: 34852770 DOI: 10.1186/s12885-021-09011-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wei Z, Zheng D, Pi W, Qiu Y, Xia K, Guo W. Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway. J Bone Oncol 2023;38:100468. [PMID: 36685044 DOI: 10.1016/j.jbo.2023.100468] [Reference Citation Analysis]
2 Hanwen Huang, Weibin Wu, Yiyu Lu, Xiaofen Pan. The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma. J Thorac Dis 2022;14. [PMID: 36389308 DOI: 10.21037/jtd-22-1185] [Reference Citation Analysis]
3 Huang L, Zhang J, Gong F, Han Y, Huang X, Luo W, Cai H, Zhang F. Identification and validation of ferroptosis-related lncRNA signatures as a novel prognostic model for glioma. Front Genet 2022;13:927142. [DOI: 10.3389/fgene.2022.927142] [Reference Citation Analysis]
4 Xu C, He T, Shao X, Gao L, Cao L. m6A-related lncRNAs are potential biomarkers for the prognosis of COAD patients. Front Oncol 2022;12:920023. [DOI: 10.3389/fonc.2022.920023] [Reference Citation Analysis]
5 Han J, Kong H, Wang X, Zhang XA. Novel insights into the interaction between N6-methyladenosine methylation and noncoding RNAs in musculoskeletal disorders. Cell Prolif 2022;:e13294. [PMID: 35735243 DOI: 10.1111/cpr.13294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chen Y, Miao L, Lin H, Zhuo Z, He J. The role of m6A modification in pediatric cancer. Biochim Biophys Acta Rev Cancer 2022;1877:188691. [PMID: 35122883 DOI: 10.1016/j.bbcan.2022.188691] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345